Sarepta Announces FDA Approval of ELEVIDYS

(20:56)

Sarepta CEO on what's next after expanded muscular dystrophy drug approval

(5:43)

SareptaCircle Event: A Journey Toward Acceptance and Hope - September 20, 2022

(1:4:27)

Keeping patients at the forefront of everything we do

(51)

Sarepta ESGCT 2024

(1:3)

Sarepta CEO Doug Ingram: We should be profitable by the end of next year if we achieve our goals

(3:31)

Watch CNBC's full interview with Sarepta CEO Doug Ingram

(4:9)

\

(12:9)

Very good news for muscular dystrophy patients ! DMD treatment ! Dr Ashfaque Khan phd! 9837616428

(15:5)

Living with LGMD - Three perspectives

(5:19)

Catalent Senior Executives Announce Leadership Transition

(4:51)

Satellos Bioscience (MSCL) - Chief Technology Officer Phil Lambert Discusses SAT-3153 Study Results

(13:26)

Gene Therapy -- The time is now: Nick Leschly at TEDxBoston

(15:27)

Saturday Panel Discussion | 2024 FAST Global Summit on Angelman Syndrome

(44:1econd)

Duchenne Muscular Dystrophy (DMD) Mechanism of Disease

(3:31)

CLINICAL TRIAL UPDATES for LGMD, 2023 (Part 1)

(1:2:22)

Elijah and the Widow at Zarephath | 1 Kings 17 Elijah Fed by Ravens Elijah Announces a Great Drought

(4:34)

Sarepta' SRP-9001, Gene Therapy to Treat Duchenne Muscular Dystrophy gets FDA Ad Comm recommendation

(1:16)

Sarepta shares tumble as concerns mount over FDA approval on gene therapy

(2:47)

Sarepta completes accelerated approval application for golodirsen

(42)

SareptAssist - How Duchenne Families Motivate Our Team

(47)

Sarepta CNBC Halftime Report 5/20

(3:31)

Duchenne Muscular Dystrophy: Could Gene Therapy Be the Answer? Exploring SRP-9001

(5:57)

Clinical Hold Lifted on Sarepta (September 2018)

(47)

SareptAssist - Duchenne Support \u0026 Resources

(52)

Upcoming Gene Therapy Trials for LGMD2B and 2I

(8:53)

Gene therapy trial in muscular dystrophy patients shows exciting results

(4:28)

[Community Update Call] Sarepta \u0026 Summit - October 2016

(47:29)

Former CEO of Sarepta Discusses the Current Duchenne Drug Landscape

(1:18)